Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
NEW QUEBEC GRAPHITE TRANSFORMATION STUDY FOR LAC CARHEIL PROJECT DELIVERS IMPRESSIVE ECONOMIC RESULTS
Canada One Announces 2026 Two-Phase Exploration Program to Advance High-Priority Porphyry Targets at Copper Dome
